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Abstract
The SynGAP protein is a major regulator of synapse biology and neural circuit func-
tion. Genetic variants linked to epilepsy and intellectual disability disrupt synaptic 
function and neural excitability. SynGAP has been involved in multiple signaling path-
ways and can regulate small GTPases with very different roles. Yet, the molecular 
bases behind this pleiotropy are poorly understood. We hypothesize that different 
SynGAP isoforms will mediate different sets of functions and that deciphering their 
spatio-temporal expression and subcellular localization will accelerate understand-
ing their multiple functions. Using isoform-specific antibodies recognizing SynGAP 
in mouse and human samples we found distinctive developmental expression pat-
terns for all SynGAP isoforms in five mouse brain areas. Particularly noticeable was 
the delayed expression of SynGAP-α1 isoforms, which directly bind to postsynaptic 
density-95, in cortex and hippocampus during the first 2 weeks of postnatal develop-
ment. Suggesting that during this period other isoforms would have a more promi-
nent role. Furthermore, we observed subcellular localization differences between 
isoforms, particularly throughout postnatal development. Consistent with previous 
reports, SynGAP was enriched in the postsynaptic density in the mature forebrain. 
However, SynGAP was predominantly found in non-synaptic locations in a period of 
early postnatal development highly sensitive to SynGAP levels. While, α1 isoforms 
were always found enriched in the postsynaptic density, α2 isoforms changed from 
a non-synaptic to a mostly postsynaptic density localization with age and β isoforms 
were always found enriched in non-synaptic locations. The differential expression 
and subcellular distribution of SynGAP isoforms may contribute to isoform-specific 
regulation of small GTPases, explaining SynGAP pleiotropy.
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1  | INTRODUC TION
De novo mutations in the human SYNGAP1 gene resulting in ge-
netic haploinsufficiency cause mental retardation type 5 (MRD-5; 
OMIM #612621), an autosomal dominant form of intellectual dis-
ability (ID) with high rates of progressively worsening childhood ep-
ilepsy (Agarwal, Johnston, & Stafstrom, 2019; Hamdan et al., 2009; 
Mignot et al., 2016; Parker et al., 2015; Vlaskamp et al., 2019). This 
debilitating neurodevelopmental disorder is estimated to be respon-
sible for up to 1% of all cases of ID (Berryer et al., 2013). Studies in 
mouse models of this condition indicate that a Syngap1 genetic defi-
cit during specific developmental stages causes premature synaptic 
maturation in excitatory neurons that result in enhanced neuronal 
excitability (Aceti et al., 2014; Clement et al., 2012; Clement, Ozkan, 
Aceti, Miller, & Rumbaugh, 2013; Ozkan et al., 2014). In addition, 
more recent studies have identified non-developmental functions of 
the Syngap1 gene that contribute to memory expression and seizure 
threshold (Creson et al., 2019). Together, these findings indicate that 
Syngap1 is critical for brain cell function. Thus, in depth study of this 
gene will provide insights into the molecular and cellular processes 
that contribute to neurological and psychiatric disorders.
Syngap1 encodes the synaptic Ras/Rap GTPase-activating pro-
tein (SynGAP), which was first described as one of the most abun-
dant components of the postsynaptic density (Chen, Rojas-Soto, 
Oguni, & Kennedy, 1998; Kim, Liao, Lau, & Huganir, 1998). Indeed, 
this protein regulates the structure and function of excitatory syn-
apses in the mammalian forebrain (Jeyabalan & Clement, 2016; 
Kilinc et al., 2018). SynGAP has a prominent role in the molecular 
mechanisms governing synaptic plasticity, being involved in the two 
hallmarks of this process, incorporation of AMPA receptors into the 
synaptic plasma membrane (Kim, Lee, Takamiya, & Huganir, 2003; 
Rumbaugh, Adams, Kim, & Huganir, 2006) and dendritic spine en-
largement (Aceti et al., 2014; Vazquez, Chen, Sokolova, Knuesel, 
& Kennedy, 2004). The activity of SynGAP toward small GTPases 
is considered to be its key functional role, with the other domains 
and sequence motifs being involved in regulating it. For instance, 
the C2 domain is key in the GAP activity toward Rap GTPases (Pena 
et al., 2008) and phosphorylation determines substrate specific-
ity, as CaMK2α promotes RapGAP activity while CDK5 and PLK2 
stimulate RasGAP activity (Walkup, Sweredoski, Graham, Hess, & 
Kennedy, 2018; Walkup et al., 2015). The exact role of sequences 
such as the pleckstrin homology (PH) domain, the SH3-binding, 
or poly-histidine motifs in the function of SynGAP are not yet un-
derstood. In vitro studies with purified proteins have shown that 
SynGAP directly modulates the activity of HRas (Kim et al., 1998), 
Rap1 (Krapivinsky, Medina, Krapivinsky, Gapon, & Clapham, 2004), 
Rap2 (Walkup et al., 2015), and Rab5 (Tomoda, 2004). Furthermore, 
Syngap1± mice present increased levels of GTP-bound Rac1 in fore-
brain extracts (Carlisle, Manzerra, Marcora, & Kennedy, 2008), indi-
cating that SynGAP also regulates Rac1, either directly or indirectly. 
The GAP activity of SynGAP participates in the regulation of several 
important signaling pathways for synaptic physiology, such as Ras-
MAPK (Komiyama et al., 2002), Ras-PI3K (Qin et al., 2005), Rap-p38 
(Krapivinsky et al., 2004; Zhu, Qin, Zhao, Aelst, & Malinow, 2002), 
and Rac1-PAK (Carlisle et al., 2008).
It remains unclear how SynGAP can have such a broad im-
pact on neuronal signaling. Alternative splicing of Syngap1 mRNA, 
which results in many protein isoforms, is likely one mechanism. 
In mammals, the Syngap1 gene encodes different protein isoforms 
that differ in their N- and C-terminus (Chen et al., 1998; Kim et al., 
1998; Li et al., 2001; McMahon et al., 2012). The central part of the 
protein is thus common to all isoforms and accounts for most of it, 
extending 1,091 residues (>80% of the longest protein isoform) in 
rat and human. This core region presents a truncated PH domain, 
lacking the first 24 residues, a C2 domain, a GTPase-activating 
protein (GAP) domain, a large disordered region of around 600 
residues and, finally, a truncated coiled-coil domain lacking its 
final 11 residues, which is involved in SynGAP multimerization 
(Zeng et al., 2016). Five N-terminal (A1, A2, B, C, and D) and four 
C-terminal (α1, α2, β, and γ) SynGAP variants have been described. 
Of the 20 possible combinations of N- and C-termini with the core 
region, 13 have been reported either in NCBI, ENSEMBL, or the 
literature (Chen et al., 1998; Kim et al., 1998; Li et al., 2001). In 
mouse, SynGAP isoforms will vary in their molecular weight, rang-
ing between 148.3 kDa (SynGAP/A2-α2, the largest) and 121.4 kDa 
(SynGAP/C-β, the smallest). Isoforms with A1/2, B, and D N-termini 
present an entire PH domain, while isoforms containing the C 
N-terminal do not include its first 24 residues. At the other end of 
the protein, isoforms with C-terminal variants α1, α2, and γ pres-
ent an entire coiled-coil domain, while those with the β variant lack 
its last 11 residues. In support of the idea that Syngap1 alternative 
splicing alters protein function, the distinct C-terminal spliced se-
quences have been shown to cause opposing effects on synaptic 
strength, with α1 driving synaptic depression (McMahon et al., 
2012; Rumbaugh et al., 2006) and α2 driving synaptic potentiation 
(McMahon et al., 2012).
Thus, the multitude of available N- and C-termini likely bestows 
distinctive functional properties to SynGAP isoforms. However, the 
expression pattern and subcellular localization of distinct SynGAP 
isoforms remain largely unexplored, particularly during early 
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postnatal development, when SynGAP is known to have a strong 
impact on synaptic (Clement et al., 2012, 2013) or dendritic (Aceti 
et al., 2014; Michaelson et al., 2018) maturation and neuronal devel-
opment (Muhia, Yee, Feldon, Markopoulos, & Knuesel, 2010; Agarwal 
et al., 2019). Here, we present a systematic study of the expression 
of SynGAP isoforms in five different brain regions and four postnatal 
developmental stages, identifying specific expression patterns for all 
isoforms, both between brain regions and throughout development. 
Furthermore, we investigate the differential subcellular localization 
of SynGAP isoforms and describe how this varies during cortical de-
velopment. Together, our data illustrates the complexity of SynGAP 
roles within brain cells, and the key role that C-term variants are likely 
to play in SynGAP biology. We also find that SynGAP C-termini are 
important for its subcellular localization and that SynGAP, generally 
regarded as almost exclusively found at the synapse, is very abun-
dant in the cytosol, specially early in postnatal development, when 
the brain is most sensitive to Syngap1 haploinsufficiency (Aceti et al., 
2014; Clement et al., 2012; Ozkan et al., 2014).
2  | MATERIAL S AND METHODS
2.1 | Ethics statement and procedures on human 
cortical samples
All surgical procedures were approved by the Ethics Committee on 
Clinical Research from the Hospital de la Santa Creu i Sant Pau (ap-
proval reference number 16/041). All samples collected originated 
from neuro-oncological surgery unit at the Hospital de Sant Pau i la 
Santa Creu between 2016 and 2018. Adult healthy cortical samples, 
as determined by pre-surgery nuclear magnetic resonance, were col-
lected in those cases that a corticectomy had to be performed to access 
subcortical pathological tissue. All patients were informed and signed 
an informed consent. Resected tissue was rapidly wrapped in aluminum 
foil and snap-frozen in liquid nitrogen. Samples were stored in −80°C.
2.2 | Ethics statement on animal research and 
animal handling
All procedures, unless specifically indicated, were done with 
C56BL/6J mice (Jackson Laboratories, Research Resource Identifier, 
RRID:MGI:5656552) in accordance with national and European leg-
islation (Decret 214/1997 and RD 53/2013). These were approved 
by the Ethics Committee on Animal Research from the Institut de 
Recerca de l´Hospital de la Santa Creu i Sant Pau (IR-HSCP) and 
the Departament de Territori i Sostenibilitat from the Generalitat 
de Catalunya (approval reference num. 9,655). Maintenance, treat-
ment and experimental procedures with mice were conducted at the 
Animal Facility of the IR-HSCP. Mice were housed at a 12 hr light/
dark cycle with fresh water and food ad libitum. No more than five 
mice of a given gender were place in the same cage. Special chow 
(T.2019.12, Envigo) was administered to pregnant mothers and litter 
until weaning (postnatal day [PND] 21), whereas adult mice were fed 
with regular chow (T.2014.12; Envigo). The total number of animals 
used to conduct mass spectrometry (MS)-based, spatio-temporal ex-
pression, and subcellular localization studies was 135. The specific 
number of animals used per age was: PND0/1:24, PND4: 28, PND7: 
6, PND11: 43, PND14: 6, PND21: 13, PND56: 15 (See Figure 1). For 
ages between PND0 and 21, female and male mice were used at 
equal ratios. PND56 mice were males. Mice culling between PND0 
and 4 was performed by head dissection or by cervical dislocation 
from that age onwards without the use of anesthetic in any case and 
minimizing animal suffering. All experiments were conducted from 
9 a.m. to 9 p.m. and those animals that were clearly smaller than the 
rest of the littermates were excluded for subsequent analyses.
2.3 | Mouse brain dissection
Mouse heads were soaked with chilled 1× phosphate-buffered sa-
line (PBS, 0.144 M NaCl, 2.683 KCl mM, 10.144 mM Na2HPO4, 
0.735 mM KH2PO4, [P5368-10PAK from Sigma]) and dissected 
using scalpel blades while placed onto a glass petri dish with a fil-
ter paper (Merck-Millipore). The skull and meninges were removed 
from brain using Iris scissors (PMD120; Thermo Scientific) and tissue 
forceps 1:2 (PMD023445; Thermo Scientific). For brain dissection 
of PND0-7 animals a magnifying loupe (Olympus KC 1,500 Ledplus; 
Olympus) was used. Brain areas were dissected as previously de-
scribed (Spijker, 2011). Tissue weight was recorded before snap-
freezing in liquid nitrogen and stored in a −80°C freezer.
2.4 | Anti-SynGAP-β antibody generation
SynGAP-β antibody was raised against SynGAP aa.1273–1285 at 
the research laboratory of Prof. Richard L. Huganir, Johns Hopkins 
University. The antigen peptide with N-terminus Cysteine (NH2-
CGGGGAAPGPPRHG-COOH) was coupled with keyhole limpet 
hemocyanin (77,600; Thermo Fisher). The antigen was injected into 
rabbit and antisera were collected after primary and several booster 
injections. Antisera were further purified with affinity column con-
taining sulfo-link coupling resin (20,401; Thermo Fisher) coupled 
with same antigen peptide. This antibody will be shared upon rea-
sonable request.
2.5 | Total protein extraction, subcellular 
fractionation and protein quantification
For extraction of total proteins, samples were mixed with chilled 
buffer (50 mM Tris-HCl pH 9 [T1503-1KG], 1% sodium deoxycho-
late [30970-100G], 50 mM NaF [106449, Merck-Millipore], 20 mM 
ZnCl2 [96468-50G], 1 mM sodium orthovanadate [S6508-10G], 
1:2,500 phenyl methane sulfonyl fluoride [P7626-5G], 2 μg/ml 
aprotinin [616370-10MG, Merck-Millipore], and 2 μg/ml leupeptin 
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[108976-10MG, all from Sigma-Aldrich unless indicated]) at a 1:17.5 
tissue:extraction buffer ratio (g/ml). Brain tissue was homogenized 
by 30 strokes in 1 or 7-ml borosilicate Dounce homogenizers (357542 
& 357544, glass-Teflon tissue grinder; Wheaton) depending on the 
volume of buffer required. Then, it was incubated on ice for 1 hr 
and centrifuged at 21,000 g for 30 min at 4°C in 1.5 ml centrifuge 
tubes (3810x; Eppendorf). The resulting pellet was re-homogenized 
twice following the same procedure and resulting supernatants were 
pooled. In the last re-homogenization cycle half of the initial w/v ratio 
was used. Prior to protein quantification, 1% sodium dodecyl sulfate 
(SDS) (428029-1EA; Merck-Millipore) was added to all samples.
Subcellular fractions were prepared following previously de-
scribed procedures (Bayés et al., 2012; Carlin, Grab, Cohen, & 
Siekevitz, 1980). All centrifugation steps were done at 4°C and sam-
ples were always kept in ice. Briefly, tissue was homogenized using 
7-ml glass-Teflon tissue grinders (357,544, borosilicate Dounce ho-
mogenizer; Wheaton). A 1:9 ratio was used and ~40 strokes were 
applied. Next, a 10 min centrifugation (Epp 5417R; Eppendorf) at 
1,400 g was conducted. The resulting supernatant was conserved 
and the pellet was subjected to two re-homogenizations in the same 
conditions. The three pooled supernatants were centrifuged at 700 g 
for 10 min, this sample corresponds with the S1 fraction. This was 
centrifuged 30 min at 21,000 g. The resulting soluble fraction was 
considered the cytosolic fraction, whereas the pellet obtained con-
tained all membranes. This was resuspended with sucrose 0.32 M 
and 50 mM Tris pH 7.4. A sucrose gradient was prepared with 1 ml of 
(top to bottom): sample, 0.85 M sucrose and Tris 50 mM pH 7.4; 1 M 
sucrose and Tris 50 mM pH 7.4, and 1.2 M sucrose and Tris 50 mM 
pH 7.4. Then, this gradient was centrifuged with a SW60 Ti rotor 
(Beckman Coulter) at 82,500 g for 2 hr. The interphase between su-
crose 1 and 1.2 M was recovered to obtain the synaptosome fraction. 
The rest of the gradient was centrifuged at 50,000 g 30 min in a fixed 
rotor and the resulting pellet, containing the non-synaptic membrane 
(NSM) fraction, was resuspended with 1% SDS and 50 mM Tris pH 
7,4. The synaptosome fraction was diluted to reach a final concentra-
tion of 10% sucrose with Tris 50 mM pH 7.4 and centrifuged in an Epp 
5117R centrifuge (Eppendorf) at 21,000 g during 30 min using 1.5 ml 
tubes. The resulting pellet was resuspended in Tris 50 mM pH 7.4, 1% 
Triton X-100 (93443-100Ml; Sigma-Aldrich) and maintained in ice for 
10 min. Finally, samples were centrifuged at 21,000 g during 30 min. 
As a result, Triton X-100 soluble fraction, referred as synaptic non-
PSD (SNP), and the Triton X-100 insoluble fraction enriched in post-
synaptic densities (PSDs), were obtained. Fraction protein yield was 
defined as the ratio of total protein amount (µg) by tissue weight (mg).
Protein concentration was determined using a micro-BCA pro-
tein assay kit (10249133; Thermo-Fisher Scientific). Prior to IB 
protein concentrations were corrected by silver stain (1610449, 
Silver Stain Plus™ kit; Bio-Rad).
2.6 | Protein dialyzation for detergent exchange
Dialysis was used to exchange sodium deoxycholate with Triton X-100 
from total protein extracts prior to immunoprecipitation (IP). Membranes 
for dialysis (Visking Corporation) were activated according to manufac-
turer's instructions. Samples were dialyzed over-night (ON) against the 
dialysis buffer (50 mM Tris HCl pH7.4 and 1% Triton X-100) at a v/v ratio 
of 1:1,000 in constant agitation at 4°C. After dialysis, Triton X-100 con-
centration was adjusted to 1% if required. Finally, samples were soni-
cated with an ultrasonic bath Sonicator (Thermo Fisher Scientific) at 5% 
of its maximum intensity during 45 s with 1.45 s on/off cycles.
2.7 | Immunoprecipitation
IPs were performed on total protein extracts from cortical samples 
at different ages. All IPs were performed at a protein concentration 
of 8 mg/ml. All steps were performed at 4°C in an orbital agitator 
(Stuart). The following amounts of protein were used for each IP: 
9 mg for PND0/1 (n of mice = 24), 16 mg for PND11 (n of mice = 15), 
8 mg for PND21 (n of mice = 3), and 7 mg for PND56 (n of mice = 3) 
samples. IPs were performed as described by the kit manufacturer 
(26,147, Pierce® Direct IP Kit; Thermo Fisher Scientific). A sepharose 
resin (Sigma P3391-250MG) was washed four times with condition-
ing buffer (50 mM Tris pH 7.4). Next a sample pre-clearing step was 
performed by mixing it with washed resin for 2 hr at 4°C. Pre-cleared 
sample was mixed with an anti-SynGAP antibody recognizing an 
epitope common to all its isoforms (5540S; Cell Signaling Technology 
[RRID:AB_10695900]) at a 1:15 (v:v) ratio ON. Each 200 μL of pre-
cleared sample were incubated with 7.5 μL of A sepharose resin dur-
ing 3 hr. A 100 g centrifugation step in a column was performed to 
recover the resin. Resin was washed three times with dialysis buffer 
and once with conditioning buffer. Bound protein was eluted with 15 
μL of the acidic elution buffer from the kit during 10 min.
2.8 | Protein electrophoresis
Protein samples for electrophoresis were prepared with 1× Laemmli 
loading sample buffer (50 mM Tris-HCl, pH 6.8; 2% SDS; 1% 
β-mercaptoethanol [M6250-100 ml], and 0.04% bromophenol blue 
[B5525-5g, all from Sigma-Aldrich]) and 10% glycerol (Sigma-Aldrich) 
F I G U R E  1   Study timeline for developmental expression and subcellular localization studies. Postnatal day (PND) indicates postnatal 
day of tissue collection. The total number of animals used for discovery MS-based studies, spatio-temporal expression and subcellular 
distribution of SynGAP and its isoforms at each PND is also indicated
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and heated at 95°C for 5 min. TGX Stain-Free™ gels (161-0181 & 
161-0185, SF gels; Bio-Rad) were prepared and activated accord-
ing to manufacturer's instructions. All blue or kaleidoscope preci-
sion plus protein standards (Bio-Rad) were used as well as a vertical 
MiniProtean system kit (Bio-rad) and 1× running buffer (0.025 M 
TRIS pH 8.4; 0.187 M glycine [G8898-1KG; Sigma-Aldrich] and 0.1% 
SDS). Electrophoretic conditions were 25 mAmp per each 0.75 mm 
wide gel or 50 mAmp per each 1.5 mm wide gel.
Proteins resolved in SDS–PAGE gels were stained ON at 22°C 
with Coomassie solution (B8522-1EA; Sigma-Aldrich). Gels were 
washed with 2.5% acetic acid (45740-1L-F; Sigma-Aldrich) and 20% 
methanol during 10 min in a rocking platform shaker (Stuart) and 
later with subsequent washes of 20% methanol, until protein bands 
were clearly visible. Gel images were acquired with ChemiDoc XRS+ 
(Bio-Rad) and quantified with Image Studio Lite ver. 3.1 (LI-COR 
Biosciences).
2.9 | Immunoblot
Protein transference was conducted using the MiniProtean kit 
(Bio-Rad), and 1× chilled transference buffer (20% methanol 
[A3493.5000; Panreac]; 39 mM Glycine; 48 mM TRIS; 0.04% SDS). 
Proteins were transferred into methanol pre-activated polyvi-
nylidene fluoride (PVDF) membranes (IPFL00010, Immobilon-P; 
Merck-Millipore). After transference, PVDF membranes were 
blocked with 5 ml Odissey blocking solution (927-50000; LI-COR) 
prepared with 1× tris-buffered saline (TBS) [50 mM Tris·HCl pH7.4; 
1,5 M NaCl [443824T]) and 0.1% sodic azide [S2002-100G, all 
from Sigma-Aldrich]) and incubated in a roller mixer (Stuart) with 
primary antibody solution ON at 4°C or 2 hr at 22°C. Commercial 
primary antibodies were: total SynGAP (tSynGAP) (NBP2-27541; 
Novus Biologicals, [RRID:AB_2810282] and Thermo PA1-046, 
[RRID:AB_2287112], only in Figure S2) at 1:2,500 and 1:2,000 di-
lution, SynGAP-α1 (06-900; EMD Millipore, [RRID:AB 1163503]) 
at 1:1,000, SynGAP-α2 (04-1071 [EPR2883Y]; Merck-Millipore, 
[RRID:AB_1977520]) used at 1:2,000 dilution, PSD-95 (3,450; Cell 
Signaling, [RRID:AB_2292883]) at 1:1,000, Gephyrin (ab32206; 
Abcam, [RRID:AB_2112628]) at 1:500, CaMK2α (05-532; Merck-
Millipore, [AB_309787]) at 1:1,000, GAD67 (MAB5406 [1G10.2]; 
Merck-Millipore, [RRID:AB_2278725]) at 1:500, Synaptophysin 
(Ab8049; Abcam [SY38], [RRID:AB_2198854]) at 1:1,000 and 
GAPDH (ab9484; Abcam, [RRID:AB_307274]) at 1:500 dilution. 
Membranes were washed four times with 1× T-TBS for 5 min before 
incubation for 1 hr at 22°C protected from light with 5 ml of the fol-
lowing secondary antibodies. Secondary antibodies were prepared 
with T-TBS (50 mM Tris·HCl pH7.4, 1.5 M NaCl, 0.1% Tween20, 
all from Sigma-Aldrich) at 1:7,500 dilution: anti-rabbit (926-
68073, IRDye 680CW, [AB_10954442]), anti-mouse (926-32212, 
IRDye 800CW [RRID:AB_621847] or 925-68072, IRDye 680RD, 
[RRID:AB_2814912]) and anti-goat (926-32214, IRDye 800CW, 
[RRID:AB_621846]). Membranes were re-blotted without prior 
stripping by an ON incubation at 4°C or 2 hr at 22°C, depending 
on the antibody. Images were acquired with an Odissey Scanner 
(LI-COR Biosciences) and protein bands were analyzed with Image 
Studio Lite ver. 3.1 software (LI-COR Biosciences). Membranes 
transferred from TGX Stain-Free™ gels were imaged and quantified 
for posterior normalization steps prior to blocking with a ChemiDoc 
XRS+ (Bio-Rad) using the Image Lab software (Bio-Rad).
2.10 | Normalization of immunoblot data
In spatio-temporal protein expression studies, band intensity units 
(IUs) were first corrected for immunoblot technical variability using 
the value of total protein transferred to PVDF membranes ob-
tained from the TGX Stain-FreeTM quantification (IU/protein inten-
sity). Corrected IUs were then normalized using the average IU of 
all bands in a blot. This normalization removed the technical vari-
ability between blots allowing to accumulate data from immunoblot 
replicates.
In subcellular localization studies, we first corrected band IU (e.g. 
tSynGAP in PSD) per amount of total protein used for immunoblot-
ting (e.g. tSynGAP IU in PSD/µg PSD protein). These values were 
next multiplied by protein yield (with units: µg protein/mg tissue) 
of their corresponding subcellular fraction, which retrieved a value 
of specific protein abundance per fraction (e.g. tSynGAP IU in PSD/
mg tissue). Finally, these values were normalized by the abundance 
in the starting homogenate (S1 fraction; e.g. tSynGAP IU in PSD/
tSynGAP IU in S1). This normalization step allowed accumulating 
data from immunoblot replicas and compare subcellular distribution 
between antibodies.
2.11 | Sample preparation and mass spectrometry-
based proteomics
Proteins were separated by SDS-PAGE and were stained with 
Coomassie (Bio-Rad). Bands between ~120–200 kDa were excised 
from acrylamide gels in a transilluminator (22V; Cultex) using scalpel 
blades. Excised gel bands were subjected to an in-gel digestion pro-
tocol being first reduced with 10 mM dithiothreitol (Sigma-Aldrich) 
and alkylated with 55 mM iodoacetamide (8.04744.0025; Sigma-
Aldrich), and later digested with trypsin (V5111; Promega Biotech 
Ibérica). Tryptic peptides were eluted from acrylamide and around 
80% of each trypsin-digested sample was injected in a linear trap 
quadrupole (LTQ) Orbitrap VelosPro with a short chromatographic 
method (40 min gradient) in a 25 cm 1.9 µm column. To avoid carry 
over, BSA runs were added between samples. BSA controls were in-
cluded both in the digestion and LC-MS/MS analyses for quality con-
trol. This experiment was done twice. The data were searched using 
an internal version of the search algorithm Mascot (Matrix Science) 
against a SynGAP (May 2014) homemade database. The Mascot da-
tabase server search was done with Protein Discoverer ver. 1.4.1.14 
(DBVer.:79) using the following search parameters: mass precision of 
2 ppm; precursor mass range of 250 Da to 5,000 Da; Trypsin with a 
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maximum of three miss-cleavages; the peptide cut-off score was set 
at 10 and peptide without protein cut-off was set at 5. Peptides were 
filtered based on IonScore >20. The precursor mass tolerance (MS) 
was set at 7 ppm and fragment mass tolerance (MS/MS) was set at 
0.5 Da with two variable modifications: oxidation (M) and acetyla-
tion (protein N-term), and one fixed modification (C): carbamidome-
thyl. False discovery rates determined by reverse database searches 
and empirical analyses of the distributions of mass deviation and 
Mascot Ion Scores were used to establish score and mass accuracy 
filters. Application of these filters to this dataset was below 1% false 
discovery rates as assessed by reverse database searching.
2.12 | Primary neuronal and cell culture, 
transfection, fluorescent immunostaining, and imaging
Hippocampal neurons from PND0 Syngap1flox/flox (Clement 
et al., 2012, 2013) mice were plated on poly-D-lysine (P6407; 
Sigma-Aldrich) coated coverslips and infected with AAV.CaMK2α.
Cre (RRID:Addgene_105558) to obtain Syngap1-/-cells. Cultures were 
maintained in Neurobasal-A media (12348–017) containing 10 µg/ml 
Gentamycin (15750060), 2 mM Glutamax (35050061), and 2% B27 
(17504044, all from GIBCO). At days in vitro (DIV) 4, cells were treated 
with 1 µM Ara-C to prevent excessive glial proliferation. At DIV18, 
cells were transfected with plasmids encoding enhanced green fluo-
rescent protein-tagged full-length SynGAP C-terminal isoforms using 
NeuroMag (NM50500, OZBiosciences) in accordance with manufac-
turer's instructions. Following an ON incubation, neurons were fixed 
for 5 min at 22°C in PBS containing 4% paraformaldehyde (PFA)/4% 
sucrose and thoroughly washed with PBS. Neurons were permeabi-
lized with 0.2% Triton-X for 10 min and blocked with 10% normal goat 
serum in PBS for 1 hr. Samples were then incubated with Alexa Fluor 
488 conjugated anti-enhanced green fluorescent protein antibody (A-
21311; Thermo Fisher Scientific, [RRID:AB_2214]) in PBS with 5% goat 
serum at 4°C ON. Coverslips were washed multiple times with PBS 
and mounted onto glass slides using Prolong Glass mounting medium. 
Images were obtained using a FV1000 Olympus laser scanning confo-
cal microscope. For anti-SynGAP-beta antibody validation, HEK293T 
Cells (Kind gift of Joseph Kissil) were cultured in DMEM media con-
taining 10% fetal bovine serum and penicillin/streptomycin. Pools of 
these cells were transfected with GFP-tagged SynGAP cDNAs con-
taining one of the four known C-term spliced sequences. 
2.13 | Data statistical analyses
Statistical tests used are indicated in figure legends, together with 
the exact number of biological and technical replicates. GraphPAD 
Prism ver. 6.0 (GraphPad) was used to conduct statistical analyses. 
When required data were assessed for normal distribution by de-
scriptive statistic measures (mean and median) and applying the 
Shapiro-Wilk and Kolmogorov–Smirnov tests. All statistical analyses 
were conducted with a significance level of α = 0.05 (p ≤ .05). No test 
for outliers was done, no data points were excluded and no blinding 
was performed. No statistical method was used to determine sam-
ple size, which was determined based on the previous experience of 
the group with the goal to minimize the number of animals required. 
Also, no randomization was performed to allocate subjects in this 
study and this study was not pre-registered.
3  | RESULTS
3.1 | Total SynGAP protein expression is different 
between brain regions and changes throughout 
postnatal development
Using an antibody that recognizes a sequence common to all SynGAP 
isoforms we have analyzed by immunoblot the abundance of all of 
them together, what we have called total SynGAP (tSynGAP). We have 
investigated tSynGAP expression in five mouse brain regions (cortex, 
hippocampus, striatum, olfactory bulb, and cerebellum) at 4, 11, 21, 
and 56 postnatal days (PND) of life (Figure 2). Depending on the tis-
sue, tSynGAP presents three patterns of developmental expression 
(Figure 2a). In cortex and hippocampus, tSynGAP increases sharply, 
reaching its maximum at PND21, and remaining at this level until 
PND56. Between PND4 and PND21, tSynGAP levels increase over six 
times in both tissues. Striatum presents a different pattern: tSynGAP 
expression is maintained constant between PND11 and PND21, and 
its maximum level is not reached until PND56. Yet tSynGAP levels also 
increase notably, also around six times, between PND4 and 56. Finally, 
both the olfactory bulb (OB) and the cerebellum present a very mod-
est, albeit significant, increase in tSynGAP levels. Between PNDs 4 and 
56, tSynGAP increases 1.7 times in OB and 1.2 in cerebellum.
We have also investigated how tSynGAP levels compare between 
tissues at each of these four developmental stages (Figure 2b). Early in 
postnatal development tSynGAP levels are very similar in cortex, hip-
pocampus, striatum, and OB, while cerebellum already presents the 
lowest levels. At PND4 there is approximately 2.5 times more tSyn-
GAP in forebrain regions than in cerebellum. This difference becomes 
larger with age, reaching a maximum difference of 30 times when 
comparing hippocampal and cerebellar expression at PND21/56 or 
cortical and cerebellar expression at PND21. As mice develop, the 
levels of tSynGAP in OB also lag behind those of the other forebrain 
areas (Figure 2b), being the maximum difference at PND21, when 
cortex and hippocampus express seven times more tSynGAP than 
OB. At PND11, cortex and striatum display similar levels of tSynGAP, 
while hippocampus presents a slight, but significantly higher abun-
dance, being the tissue with the highest tSynGAP levels at this age. 
At PND21, cortical and hippocampal tSynGAP have similar levels, 
presenting almost twice as much tSynGAP than striatum. This is in 
agreement with the sustained tSynGAP levels previously observed in 
striatum between PND11 and 21 (Figure 2a). Finally, at PND56, the 
abundance profile of tSynGAP at cortex, hippocampus, and striatum is 
very similar to that found at PND11. Cortex and striatum have similar 
abundance, while hippocampus presents significantly more tSynGAP.
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3.2 | In silico identification and experimental 
validation of novel Syngap1 splice variants
ENSEMBL, NCBI-Gene, and UniProt (as of 02 May 2019), together 
with the previous literature (Chen et al., 1998; Kim et al., 1998), re-
port a total of 15, 9, and 7 Syngap1 transcripts in mouse, rat, and 
human respectively (Table S1). Remarkably, there is still little overlap 
between these databases. For instance, in mouse, only two proteins 
can be directly related between ENSEMBL and NCBI. Interestingly, 
the NCBI Gene database identifies unpublished variants in mice 
(four N-terminal and one C-terminal). We refer to these unreported 
N-terminals as A3, A4, E, and F, whereas the C-terminal one as α3 
(Table S1 and Figure S1). The first two N-term variants are shorter 
versions of A1/2, E presents a unique N-terminus, and F starts at resi-
due 430 inside the core of SynGAP. If the F variant is expressed at the 
protein level, it would lack the PH, C2, and GAP domains, which could 
be functionally relevant to neuronal biology. In order to investigate 
if any of these predicted variants is expressed at the protein level, 
we immunoprecipitated tSynGAP from mouse cortex at four postna-
tal stages (PND0/1, 11, 21, and 56) and performed high-throughput 
MS-based proteomics. However, we could not identify unique pep-
tides for any of these variants. Instead, we identified a unique pep-
tide corresponding to the first residues of the D N-terminus (Table 
S2), which had only been reported at the RNA level (Li et al., 2001). 
Importantly, this peptide presented an acetylated initial methionine, 
which is a common post-translational modification of the N-terminus 
(Varland, Osberg, & Arnesen, 2015). The rat D variant was originally 
submitted (Li et al., 2001) to NCBI as an artifactual sequence resulting 
from the fusion of transcripts from two different genes, as reported 
later (McMahon et al., 2012), and thus considered nonexistent. Yet, 
our proteomics experiments identify the acetylated N-terminus of 
the D variant in cortical samples from all ages investigated. The re-
current identification of this acetylated N-terminal peptide provides 
strong evidence for the expression of this variant in mouse cortex.
3.3 | SynGAP isoforms present different 
developmental expression patterns
SynGAP isoforms present four different C-terminal variants 
that have been identified at the protein level, which are named 
F I G U R E  2   Abundance of total SynGAP (tSynGAP) in five different brain regions and four postnatal stages. (a) Developmental changes in 
tSynGAP abundance in five different brain regions (cortex, hippocampus, striatum, olfactory bulb, and cerebellum). Ages investigated were 
postnatal day (PND) 4, 11, 21, and 56. (a1) Representative immunoblots showing tSynGAP abundance in each of the five tissues. (a2) Box and 
whiskers plots depict the mean of normalized protein abundance data derived from immunoblot intensity (N: cortex 14–20, hippocampus 
12–16, striatum 6–7, olfactory bulb 11–16, and cerebellum 23–24). N indicates total number of technical replicates from a pool of a given 
brain area coming from of a minimum of two mice. The standard error of the mean (SEM) is also shown. Mean differences were analyzed by 
one-way ANOVA followed by Tukey's post-hoc test, ***p < .001, **p < .01, and *p < .05. (b) Brain region changes in tSynGAP abundance in 
four life stages, including three postnatal development stages (PND4, 11, and 21) and adulthood (PND56). (b1) Representative immunoblots 
showing tSynGAP abundance in each life stage. (b2) box and whiskers plots depict the mean of normalized protein abundance data derived 
from immunoblot intensities (N: cortex 6–15, hippocampus 6–15, striatum 6–15, olfactory bulb 6–15, and cerebellum 6–15). N indicates total 
number of technical replicates from a pool of a given brain area coming from of a minimum of two mice. The standard error of the mean (SEM) 
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alpha1 (α1), alpha2 (α2), beta (β), and gamma (γ). Commercial an-
tibodies are available for two (α1 and α2) and we raised a new 
antibody that recognizes the β sequence. We confirmed that 
these three antibodies are selective by showing that they do 
not cross-react (Figure S2). In our experimental conditions, as 
in previous works (Kim et al., 1998; Li et al., 2001; McMahon 
et al., 2012; Yang, Tao-Cheng, Bayer, Reese, & Dosemeci, 2013), 
these C-terminal specific antibodies distinguish two major 
bands (Figures 3–4). These two bands correspond with at least 
two different isoforms, which will necessarily present different 
N-terminus. Notably, we have not found statistically significant 
abundance differences between the top and bottom bands in 
any of the experiments performed. This indicates that isoforms 
with the same C-terminus display equivalent expression pat-
terns along development in the five brain regions investigated. 
For this reason, we considered both bands together for subse-
quent analysis.
In cortex (Figure 3a), α1-containing SynGAP isoforms remain 
at very low levels until PND11 as compared with their maximum 
expression. Between PND11 and PND21, α1 expression increases 
fivefold, to reach over 60% of their adult (PND56) levels. In con-
trast, isoforms containing α2 and β C-term variants already present 
around 50% of their maximum abundance at PND11. Interestingly, 
α1-, α2-, and β-containing isoforms vary in their pattern of cortical 
expression. Namely, α1 isoforms do not reach their maximum until 
PND56, while α2 and β isoforms peak at PND21. Furthermore, 
while α2 isoforms maintain their maximum expression level be-
tween PND21 and 56, those of β isoforms decrease significantly 
after PND21, presenting 70% of their maximum expression at 
PND56.
The hippocampal expression pattern (Figure 3b) of the iso-
forms investigated is quite similar to that of cortex. α1 isoforms 
reach their maximum expression at PND56, while α2 does it at 
PND21 and β isoforms peak at PND21. Here, we also observed 
a decrease in β isoforms between PND21 and 56, although it did 
not reach statistical significance. Also, the abundance of α1 iso-
forms does increase between PND4 and 11, as opposed to what 
we observed in cortex. Still, α1 isoforms expression fold change 
between PND11 and PND56 is higher (4-fold) than that observed 
between PND4 and 11 (2-fold).
In striatum (Figure 3c), α1 and α2 isoforms present a biphasic 
expression pattern that we have not observed in any other tissue. 
Expression increases from PND4 to PND11 and then again between 
PND21 and PN56, but during the second and third weeks (PND11-
21) the expression of these isoforms remains constant. Striatal lev-
els of β isoforms suggest a similar pattern, as PND56 expression 
is higher than PND11 and there is no difference between PND11 
and PND21. Yet, the difference between PND21 and PND56 does 
not reach statistical significance. Thus, our data could also be inter-
preted as that β isoforms reach their maximum level at PND21 and 
then this is maintained.
In the OB and cerebellum (Figure 3d,e) we observed less de-
velopmental variation in the abundance of SynGAP isoforms, 
particularly for β isoforms, which do not present any difference 
in their expression along the postnatal period investigated. In OB, 
both α1 and α2 isoforms present a moderate increase in their ex-
pression level, showing a maximum at PND56. Finally, in cerebel-
lum, α1 levels are constant from PND11 onwards, while α2 present 
a biphasic increase in expression, with a period of latency between 
PND11 and PND21.
Overall, we observed a much better correlation in the develop-
mental expression of α1 and α2 isoforms, as this is statistically signif-
icant in all brain areas but OB and cerebellum, than between α1 and 
β isoforms, which were never found significantly correlated (Table 1). 
β isoforms present a better expression correlation with α2 isoforms, 
reaching statistical significance in hippocampus, what suggests that 
α2 isoforms would present an intermediate expression pattern be-
tween those of SynGAP α1 and β-containing isoforms.
3.4 | Developmental expression pattern of 
SynGAP-α1/α2 isoforms follows the formation of 
excitatory and inhibitory synapses
We also sought to explore if the developmental expression pro-
file of SynGAP isoforms could be linked to the temporal acquisition 
of excitatory and inhibitory synapses and/or neurons. To achieve 
this purpose we compared the expression of SynGAP isoforms to 
that of PSD-95, marker of excitatory synapses; Gephyrin, marker 
of inhibitory synapses; CaMK2α, marker of excitatory neurons; 
and GAD-67, marker of inhibitory neurons (Table 1 and Figure S3). 
Interestingly, we found better correlations when comparing the 
expression patterns of SynGAP isoforms with both synaptic mark-
ers than when comparing them with neuronal markers (Table 1). 
Indicating that, overall, the developmental expression of SynGAP 
isoforms parallels the formation of excitatory and inhibitory syn-
apses rather than the differentiation of excitatory and inhibitory 
neurons. Indeed, only a few significant correlations where found 
between the expression levels of SynGAP isoforms and CaMK2α 
or GAD-67 (Table 1).
Nevertheless, we again observed a marked difference be-
tween the expression pattern of α1/α2 and β isoforms. While the 
former correlate very well with the expression of PSD-95 and 
Gephyrin in almost all tissues investigated, β isoforms present a 
more tissue-restricted correlation with synaptic markers (Table 1). 
Actually, β isoforms only present significant correlation with the 
expression of PSD-95 in hippocampus and striatum and with 
Gephyrin in hippocampus. Importantly, we observed very high 
levels of correlation between the developmental expression pat-
tern of PSD-95 and Gephyrin in cortex, hippocampus, and striatum 
(Table 1), indicating that the incorporation of excitatory and inhib-
itory synapses occurs more or less simultaneously in these tissues 
(Oh, Lutzu, Castillo, & Kwon, 2016). Thus, it is not surprising that 
the expression of SynGAP isoforms correlates with PSD-95 but 
also with Gephyrin. Despite PSD-95 proteins may only interact di-
rectly with α1 isoforms (Kim et al., 1998), we also observed good 
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expression correlation with PSD-95 and α2 isoforms (Table 1). 
Actually, the co-expression of PSD-95 with α1 and α2 isoforms 
presented a higher correlation with α2 isoforms, as these reached 
statistical significance in almost all brain areas investigated, while 
the correlation of PSD-95 and α1 isoforms was only significant in 
cortex and OB.
F I G U R E  3   Compared protein abundance of SynGAP isoforms along postnatal development in five different brain regions. (a–e) data 
from cortex, hippocampus, striatum, olfactory bulb, and cerebellum respectively. (a1–e1) representative immunoblots for SynGAP isoforms 
containing each of the three C-terminal variants (α1, α2 and β). (a2–e2) dot plots for each brain region depicting mean normalized protein 
abundance data from each isoform derived from immunoblot intensities (N: cortex 4–19, hippocampus 6–12, striatum 3–9, olfactory bulb 
6–14, and cerebellum 8–15). N indicates total number of technical replicates from a pool of a given brain area coming from a minimum of two 
mice. The standard error of the mean (SEM) is also shown. Mean differences were analyzed by one-way ANOVA followed by Tukey's post-
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3.5 | SynGAP isoforms present different regional 
expression patterns
We next compared the abundance of SynGAP isoforms between 
brain regions in three postnatal developmental time points, PND4, 
11, 21, and in young adults (PND56). At PND4 (Figure 4a), the ex-
pression of all isoforms investigated presented equivalent levels in 
cortex, hippocampus, and striatum, while cerebellar expression was 
always the lowest. In the OB, levels of α2 and β isoforms were un-
distinguishable from those in the other forebrain areas, but α1 abun-
dance was significantly reduced, presenting the same levels found 
in cerebellum. Actually, α1 isoforms present similarly low expres-
sion levels in cerebellum and OB in all ages investigated. At PND11, 
α2 and β-containing isoforms still present higher levels in OB when 
compared with cerebellum, yet this difference disappears at PND21 
and 56, where both tissues express equally low levels of all isoforms.
After PND4, hippocampus was the region where SynGAP iso-
forms presented the highest levels (Figure 4b–d). This was already 
noticeable at PND11, although not all comparisons reached statisti-
cal significance, and very clear at PND56. Nevertheless, at PND21 
cortical expression of α1 and α2 isoforms becomes more promi-
nent. This phenomenon is particularly noticeable for the cortical 
F I G U R E  4   Compared protein abundance of SynGAP isoforms in five different brain areas along postnatal development and in adulthood 
(a–d) data from postnatal day (PND) 4, 11, 21, and 56, respectively. (a1–d1), representative immunoblots for SynGAP isoforms containing 
each of the three C-terminal variants (α1, α2, and β). (a2–d2), Dot plots for each life stage depicting normalized protein abundance data from 
each isoform derived from immunoblot intensities (N: cortex 6, hippocampus 6, striatum 6, olfactory bulb 6, and cerebellum 6). N indicates 
total number of technical replicates from a pool of a given brain area coming from of a minimum of two mice. The standard error of the mean 
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expression of α1 isoforms, which present a cortex to hippocampus 
expression ratio close to 2 at PND21, and around 0.7 at PND11 and 
PND56. Instead the cortical increase of α2 isoforms at PND21 only 
brings them to the same levels found in hippocampus. This sharp 
increase in α1 abundance specific to cortical samples from PND21 
animals exemplifies the specific regulation at which the expression 
of SynGAP isoforms can be.
3.6 | All SynGAP isoforms investigated are 
expressed in the young and old human cortex
Immunoblots of total cortical extracts from two human individuals 
with 19 and 67 years of age were performed to elucidate if SynGAP 
isoforms are expressed in this human tissue. We found expression 
of tSynGAP and all C-terminal variants in both samples (Figure S4). 
In line with the lower neuronal density found in the human cortex, 
as compared with the mouse one (Defelipe, Alonso-Nanclares, & 
Arellano, 2002), human immunoblots present a clear reduction per 
unit of protein of tSynGAP and all its isoforms. Interestingly, human 
samples presented the same two bands found in mice when investi-
gated SynGAP isoforms by the same technique.
3.7 | Differential subcellular distribution of 
tSynGAP along cortical postnatal development and in 
adult hippocampus
Next, we investigated to what extent tSynGAP presented a differ-
ential subcellular distribution throughout postnatal development. 
This study was performed with mouse cortical samples. Five sub-
cellular fractions were prepared: homogenate without nuclei (S1), 
cytosol, non-synaptic membranes (NSM), SNP and PSD (Figure S5). 
This fractionation protocol was applied to three postnatal devel-
opment stages PND7, 14 and 21 and young adult (PND56). Protein 
yield (i.e., protein amount/ tissue weight) was calculated for all 
subcellular fractions generated (Figure S5a) and used, together 
with immunoblot intensity data (Figure S5b), to obtain a measure 
of protein abundance in each fraction. Interestingly, we observed 
a decrease in the SNP yield between PND14 and 21, simultane-
ous to an increase in the PSD yield, likely reflecting the increased 
maturation of synapses during this week (Figure S5c). Subcellular 
protein markers (GAPDH, Synaptophysin, Gephyrin and PSD-95) 
were used to validate the fractionation protocol (Figure S5d).
The abundance of tSynGAP in different subcellular fractions 
was analyzed by immunoblot together with that of PSD-95 (Figures 
TA B L E  1   Postnatal development expression correlation between SynGAP isoforms and synaptic and neuronal markers
 
Pearson R correlation coefficient
Cortex Hippocampus Striatum Olfactory bulb Cerebellum
Expression correlation between SynGAP isoforms
α1 versus α2 0.95* (0.048) 0.96* (0.040) 0.99* (0.007) 0.865 0.89
α1 versus β 0.75 0.84 0.88 0.40 −0.68
α2 versus β 0.90 0.96* (0.041) 0.93 (0.074) 0.36 −0.31
Expression correlation between PSD-95 and Gephyrin
PSD-95 versus Gephyrin 0.98* (0.019) 0.99* (0.003) 0.99* (0.014) 0.12 0.90
Expression correlation between PSD-95 and SynGAP isoforms
PSD-95 versus α1 0.98* (0.025) 0.95 (0.054) 0.94 (0.063) 0.98* (0.023) 0.89
PSD-95 versusα2 0.99* (0.005) 0.99* (0.004) 0.97* (0.030) 0.94 (0.056) 0.99* (4.7e5)
PSD-95 versus β 0.87 0.97* (0.029) 0.96* (0.043) 0.42 −0.31
Expression correlation between Gephyrin and SynGAP isoforms
Gephyrin versus α1 0.93 (0.067) 0.97* (0.033) 0.93 (0.067) 0.18 0.61
Gephyrin versus α2 0.98* (0.023) 0.99* (0.003) 0.96* (0.042) 0.06 0.90
Gephyrin versus β 0.93 (0.067) 0.95* (0.049) 0.90 −0.81 0.13
Expression correlation between CaMK2α and SynGAP isoforms
CaMK2α versus α1 0.78 0.93 (0.066) 0.49 0.76 −0.95* (0.049)
CaMK2α versus α2 0.89 0.99* (0.006) 0.59 0.97* (0.026) −0.88
CaMK2α versus β 0.97* (0.03) 0.98* (0.021) 0.77 0.17 0.49
Expression correlation between GAD-67 and SynGAP isoforms
GAD-67 versus α1 0.93 (0.075) N/A 0.89 0.93 (0.067) 0.87
GAD-67 versus α2 0.99* (0.006) N/A 0.94 (0.064) 0.97* (0.03) 0.95* (0.048)
GAD-67 versus β 0.90 N/A 0.97* (0.032) 0.74 −0.23
Abbreviations: N/A, not analyzed; PSD, postsynaptic density.
*Significant correlation, p-value between parenthesis (p ≤ 0.075 also included). 
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F I G U R E  5   Subcellular distribution of total SynGAP (tSynGAP) and PSD-95 in cortex from four life stages and adult hippocampus. (a–d) 
box and whiskers plots representing the mean of normalized immunoblot intensity data (see Figure S5b) from different subcellular fractions. 
White boxes present tSynGAP data and gray boxes PSD-95 data. (N: postnatal day [PND]7 6–18, PND14 6–21, PND21 9–18, PND56 6–15). 
N indicates total number of technical replicates performed using cortical samples coming from six different mice. The standard error of 
the mean (SEM) is also shown. Mean differences were analyzed by two-way ANOVA followed by Fisher's LSD post-hoc test, ***p < .001, 
**p < .01, and *p < .05. Subcellular fractions correspond with: cytosol; NSM, non-synaptic membranes; SNP, synaptic non-PSD and PSD, 
postsynaptic density. Life stages investigated are: PND7 (a), PND14 (b), PND 21 (c), and PND56 (d). (e) Immunoblots presenting subcellular 
distribution of total SynGAP (tSynGAP), its isoforms, and PSD-95 in adult (PND56) hippocampus. Subcellular fractions investigated: 
Homogenate without the nuclear fraction (S1); cytosol; SNP, synaptic non-PSD and PSD, postsynaptic density. (f) Dot plot with the mean 
of normalized immunoblot intensity data of tSynGAP (white dots) and PSD-95 (grey dots) in the subcellular fractions obtained from adult 
hippocampus (N: PND63 6–9 technical replicates using six biological replicates resulting from a pool of two mouse hippocampus per replica). 
(g) Dot plot with mean of normalized immunoblot intensity data of SynGAP isoforms containing α1, α2, and β C-terminal variants in the 
subcellular fractions obtained from adult hippocampus. N: PND63 6–8 technical replicates using six biological replicates resulting from a 
pool of the hippocampus from two mice per replica. The standard error of the mean (SEM) is also shown. Mean differences were analyzed by 
one-way ANOVA followed by Tukey's post-hoc test ***p < .001, **p < .01, and *p < .05. (h) Mouse Syngap1 KO hippocampal neurons (DIV17) 
transfected with constructs expressing enhanced green fluorescent protein (EGFP) tagged SynGAP C-terminal isoforms (α1, α2, and β) along 
with mRuby2 (cell-fill). (i) Synaptic enrichment is calculated as the ratio of EGFP signal present in dendritic spines versus dendritic shaft. 
n = 30 spines form 9–11 neurons for each isoform analysis. Error bars indicate SEM. Mean differences were assessed by one-way ANOVA 
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5–6). Of the four subcellular fractions investigated, tSynGAP was 
essentially found in two (Figure 5a–f), cytosol and PSD. For this 
reason we generated a PSD:cytosol expression ratio to analyze 
this data. The absence or minute amount of tSynGAP in NSM and 
SNP fractions indicated that it is not associated to extra-synaptic 
membranes and, furthermore, that within the synaptosome it is 
essentially found at the PSD. Interestingly, at PND7 tSynGAP was 
largely found in the cytosol (PSD:cytosol ratio 0.1) and it is not until 
PND56 that we observed significantly more tSynGAP in the PSD 
than in the cytosolic fraction from mouse cortices (Figure 5a–d). 
At PND14 and 21, the abundance of tSynGAP at the PSD was sig-
nificantly higher than that found in the SNP fraction, yet tSynGAP 
was still more abundant in the cytosol. At PND21, the PSD:cytosol 
ratio of tSynGAP is still 0.6. Even at PND56, the remaining frac-
tion of tSynGAP at the cytosol is quite large, as this ratio is 1.7. 
This developmentally regulated subcellular expression pattern of 
tSynGAP is in stark contrast with that displayed by PSD-95, as this 
scaffolding protein is predominantly expressed at the PSD in all 
life stages investigated, presenting almost negligible levels in the 
cytosolic fraction.
We also investigated adult (PND56) subcellular localization of 
tSynGAP and its isoforms in the hippocampus (Figure 5e–g). Here, 
we could not find a significantly different expression level of tSyn-
GAP between cytosol and PSD, while PSD-95 presented a very 
restricted PSD localization. When considering the adult hippo-
campal expression of SynGAP isoforms we observed that α1 and 
α2 isoforms were enriched at the PSD, while β isoforms were very 
much enriched in the cytosolic fraction (Figure 5g). This is clearly 
indicated by the PSD:cytosol ratios found for these proteins: 3.2 for 
α1, 2.5 for α2, and 0.3 for β isoforms. We next aimed to validate 
the different subcellular localization of SynGAP isoforms observed 
in adult hippocampus using an alternative experimental approach. In 
this case we transfected primary cultures of hippocampal Syngap1-/- 
neurons with GFP-tagged forms of SynGAP presenting one of the 
three C-terminal variants, finally, we quantified GFP signal in den-
dritic spines and shafts to obtain a ratio of spine:shaft GFP signal 
(Figure 5h,i). Notably, we did found a significant difference in the 
localization of α1 and the other two isoforms, being the later more 
prominently expressed at dendritic spines, in accordance with the 
immunoblot data collected from both cortical and hippocampal 
samples.
3.8 | Differential subcellular distribution of SynGAP 
isoforms along cortical postnatal development
We also investigated the subcellular distribution of SynGAP isoforms 
along cortical postnatal development (Figure 6 & Figure S5b). As ex-
pected, in this study we also localize all isoforms at two main subcel-
lular locations, the cytosol and the PSD. We found very low levels of 
F I G U R E  6   Subcellular distribution of SynGAP isoforms along 
three postnatal developmental stages and adulthood. (a–d) Dot 
plots representing the mean of normalized immunoblot intensity 
data (see Figure S5b) from different subcellular fractions for 
SynGAP isoforms presenting three different C-terminal variants 
and PSD-95. (N: PND7 6, PND14 6–9, PND21 6–9, PND56 6–11). N 
indicates total number of technical replicates performed using six 
different mouse cortical samples. The standard error of the mean 
(SEM) is also shown. Mean differences were analyzed by one-way 
ANOVA followed by Tukey's post-hoc test, ***p < .001, **p < .01, 
and *p < .05. Subcellular fractions correspond with: cytosol; NSM, 
non-synaptic membranes; PND, postnatal day; SNP, synaptic non-
PSD and PSD, postsynaptic density. Life stages investigated are: 
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α1 isoforms early in postnatal development (PND7 & 14), as a con-
sequence their subcellular location could not be confidently estab-
lished at these ages (Figure 6a,b). At later ages, α1 isoforms presented 
a very restricted localization at the PSD (Figure 6c,d, PSD:cytosol 
ratio at PND21 and PND56 >4). Alpha2- and β-containing isoforms 
were expressed at higher levels early in development and could thus 
be localized at specific subcellular locations from PND7 to 56. These 
isoforms presented an almost exclusive cytosolic location during 
the first two postnatal weeks (Figure 6a,b, PSD:cytosol <0.2 in all 
cases), and a much-increased PSD localization between PND21 and 
PND56. Nevertheless, β isoforms were always found significantly 
more expressed in the cytosol than in the PSD, even at PND56 
where the PSD:cytosol ratio is 0.4. In contrast, α2 isoforms present 
similar expression level in cytosol and PSD at both PND21 and 56, 
as indicated by the PSD:cytosol ratio, which is of 1.5 at PND21 and 
1.9 at PND56, although PSD levels were found significantly higher. 
Therefore, subcellular localization of SynGAP isoforms in adult hip-
pocampus recapitulate the findings found in adult cortex.
4  | DISCUSSION
It is established that mammals express multiple protein isoforms 
from the Syngap1 gene, yet the complete set of SynGAP isoforms is 
still to be defined. Evidence from multiple sources, including tran-
scriptomics data, suggest that human, mouse, and rat SynGAP iso-
forms would at least have 5 N-termini (A1, A2, B, C, and D) and 4 
C-termini (α1, α2, β, and γ). Nevertheless, C and D N-termini have not 
been reported in humans and NCBI adds four extra N-termini (A3, 
A4, E, and F), and another C-terminus (α3), to the mouse set of vari-
ants. To the best of our knowledge, only the D N-terminus has been 
unambiguously identified at the protein level, which we report here 
for the first time. The fact that MS-based methods have not been 
able to identify unique peptides from the other isoforms, beyond 
peptides common to A1 and A2 (McMahon et al., 2012), suggests 
that their N-termini could be proteolyzed.
Different SynGAP isoforms have shown opposed effects in 
the control of synaptic strength (McMahon et al., 2012), to local-
ize to different subcellular compartments (Li et al., 2001; Moon, 
Sakagami, Nakayama, & Suzuki, 2008; Tomoda, 2004) or to be able 
to bind to different proteins (Kim et al., 1998; Li et al., 2001), partic-
ipating in different protein complexes and, by extension, in differ-
ent molecular functions. SynGAP-β has even been described at the 
nucleus of cortical and hippocampal neurons (Moon et al., 2008), 
which would be in agreement with the signal that the Database of 
Nuclear Localization Signals (Bernhofer et al., 2017) identifies in 
the SynGAP core region (KKRKKD). This motif would be located 
toward the end of the C2 domain, as it occurs in the Doc2g pro-
tein, which is known to translocate to the nucleus through this sig-
nal (Fukuda, Saegusa, Kanno, & Mikoshiba, 2001). For this reason, 
it is essential to find out where and when these isoforms are ex-
pressed to have a correct understanding of SynGAP biology. Using 
three highly specific antibodies /against α1, α2, and β C-termini 
we compared isoform expression levels in different mouse brain 
regions along postnatal development and in adult, as well as their 
cortical and hippocampal subcellular distribution. We have also 
shown that isoforms presenting these three C-termini are also ex-
pressed in the cortex of two human individuals aged 19 and 67. 
As previously reported (Kim et al., 1998; Li et al., 2001; McMahon 
et al., 2012; Yang et al., 2013), the three antibodies identify two 
major bands in all conditions investigated, including in human sam-
ples. This indicates that each C-terminus will at least be expressed 
with two different N-termini. Importantly, we did not observe 
significantly different expression patterns between the top and 
bottom bands, indicating that the C-termini would determine the 
differential expression observed between isoforms.
Developmental expression in each of the five tissues analyzed re-
vealed differences between SynGAP isoforms, although, overall, α1 
and α2 isoforms presented a more similar expression pattern between 
each other than with β isoforms. Developmental expression differ-
ences were most noticeable in cortex, hippocampus, and striatum. As 
in cerebellum and olfactory bulb PND4 levels remained unaltered, for 
β isoforms, or just increased moderately, for α1 and α2 isoforms. In 
cortex and hippocampus, the temporal expression of α1 isoforms is 
importantly delayed relative to that of α2 and β, as α1 isoforms reach 
their maximum at PND56, while α2 and β at PND21. Thus, α1 isoforms 
would present very low levels at PND11, during the critical period of 
Syngap1 deficiency (Clement et al., 2012, 2013), suggesting that other 
SynGAP isoforms may play a more relevant role early in this period. 
This is in agreement with our identification of unique ion peptide pre-
cursors through discovery MS studies for α2 and β from PND0 until 
PND56 and for α1 only in adulthood as well as with the observation 
that the PDZ binding motif found in α1 isoforms is not key for mediat-
ing SynGAP function in barrel cortex formation (Barnett et al., 2006). 
Interestingly, the developmental expression observed in striatum pres-
ents a bi-phasic pattern, which is unique to this brain region. Protein 
expression increases between PND4 and PND11, remains constant 
during the critical period, between PND11 and 21, and increases again 
between PND21 and PND56. This pattern is very obvious for α1 and 
α2 isoforms, while the second stage of increase, between PND21 and 
PND56, does not reach statistical significance for β isoforms.
Although SynGAP is a well-known component of excitatory syn-
apses from principal neurons, it is also expressed in inhibitory neu-
rons (Berryer et al., 2016) and it has been found co-localizing with 
Gephyrin and GAD-67 in primary neuronal cultures, especially β iso-
forms (Moon et al., 2008). We thus wanted to investigate if we could 
correlate the developmental expression pattern of SynGAP isoforms 
with the expression of markers of excitatory and inhibitory synapses 
and neurons, to investigate if different isoforms presented specific 
expression patterns relating them to the developmental processes 
of neurogenesis or synaptogenesis. Interestingly, we found that α1 
and α2 isoforms better followed the expression of synaptic markers 
than neuronal ones, while β isoforms did not systematically correlate 
with neither synaptic nor neuronal markers. Noticeably, β isoforms 
only present significant expression correlation with Gephyrin in 
hippocampus, which is in agreement for a role of these isoforms 
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in hippocampal inhibitory synapses, as previously reported (Moon 
et al., 2008).
Isoform abundance comparison between tissues revealed that 
cerebellum and olfactory bulb presented the lowest expression for 
all SynGAP isoforms, with the exception of α2 and β isoforms in 
the olfactory bulb at PND4. Isoform abundance comparison be-
tween cortex, hippocampus, and striatum revealed that at PND11 
and adulthood the highest expression was found in the hippo-
campus. Yet, at PND21, toward the closure of the critical period, 
clear differences were observed between isoforms. At this stage, 
α1 isoforms presented the highest expression levels at cortex, α2 
isoforms presented equivalent levels in cortex and hippocampus, 
while hippocampus remained the tissue with the highest expres-
sion of β isoforms. We therefore observed an increase in the corti-
cal expression of α1 and α2 isoforms relative to their hippocampal 
levels, this being particularly striking for α1 isoforms. FMRP levels 
were found decreased specifically during PND21-23 in hippocam-
pus from Syngap1± mice to compensate the necessary increase 
in the expression of SynGAP mRNA at this point of development 
(Paul et al., 2019). Taken all these data together, PND21 is a key 
age for SynGAP neurobiology.
As SynGAP was first identified in the PSD, it has mainly been 
studied in the context of adult synaptic function. Yet, Syngap1 ex-
pression starts early in embryogenesis (Porter, Komiyama, Vitalis, 
Kind, & Grant, 2005), before the onset of synaptogenesis, indicating 
that SynGAP must have non-synaptic functions. For this reason, we 
decided to investigate the distribution of SynGAP into subcellular 
compartments and if this changed along postnatal development. We 
looked for SynGAP distribution in four major cellular compartments, 
(a) cytosol, containing soluble proteins not bound to membranes 
such as GAPDH or Gephyrin, (b) non-synaptic membranes (NSM), (c) 
synapse excluding the PSD (SNP) which would include presynaptic 
proteins like Synaptophysin and (d) the PSD, and we compared it to 
the distribution of the PSD marker PSD-95. Although we detected 
SynGAP and its isoforms in all subcellular fractions investigated, 
when normalizing their abundance by the amount of protein found in 
each fraction, we observed that SynGAP largely partitions between 
two locations, the PSD and the cytosol. Indicating that SynGAP has a 
cytosolic function, which is essentially uncharacterized, and that this 
is the predominant function early in postnatal development.
tSynGAP subcellular distribution was remarkably different from 
that of PSD-95, which at PND7 was weakly expressed, but from 
PND14 onwards was almost exclusively found at the PSD. Instead, 
tSynGAP presented a clear cytosolic localization at all ages investi-
gated, even in adult cortex and hippocampus. Actually, during the 
first two postnatal weeks, tSynGAP was almost exclusively found at 
the cytosol. The fraction of tSynGAP localized to the PSD, progres-
sively increased along postnatal development but tSynGAP was only 
found significantly enriched in the PSD compared to cytosol in adult 
cortical samples. Even at PND21, when synaptogenesis is largely 
finished (Harris, 1999), tSynGAP was still found more abundant in 
the cytosol. It is also interesting to note that within synaptosomes, 
tSynGAP is almost exclusively found at the PSD, as we detected very 
low amounts of this protein at the SNP fraction, which contains all 
synaptic proteins that are not in the PSD. Different SynGAP iso-
forms presented a clearly distinctive subcellular localization pattern 
between the cytosol and the PSD. Being α1 and β isoforms the ones 
with the most opposed patterns. Alpha1 isoforms were always found 
highly restricted to the PSD, while β ones were always enriched in 
the cytosolic fraction and expressed with low levels at PSDs until 
PND21. Isoforms with the α2 C-termini presented an intermediate 
behavior, enriched in the cytosol in PND7 and 14 and enriched at 
the PSD at PND21 and 56. This differential distribution of SynGAP 
isoforms was also observed in hippocampal samples by two orthog-
onal methods, indicating that the same localization pattern could be 
found in other brain regions.
Interestingly, at PND14, when PSDs are already formed in the 
mouse cortex (Chandrasekaran et al., 2015; Swulius, Kubota, Forest, 
& Waxham, 2010), as indicated by the clear enrichment of PSD-95 
in this fraction, α2 and β-containing isoforms present very low PSD 
levels. However, 1 week later (PND21), coinciding with the rise of α1 
isoforms expression and localization to the PSD, the presence of α2 
and β isoforms in this location clearly increases. Suggesting a coop-
erative mechanism of SynGAP isoforms localization to the PSD. An 
alternative explanation would be that between PND14 and PND21 
the primary, and yet unknown, interacting point for SynGAP at the 
PSD becomes much more abundant, driving the increase in α2 and β 
isoforms at this location.
Taking into consideration that the interaction between 
SynGAP-α1 and PSD-95 is not required for SynGAP localization to 
the PSD (Barnett et al., 2006; Rumbaugh et al., 2006; Vazquez et al., 
2004) we propose a model in which all SynGAP isoforms would be 
able to locate to the PSD through primary interaction(s) with un-
identified protein(s). These putative interaction(s) would occur via 
a sequence within the core region of SynGAP. Furthermore, α1 iso-
forms would present a secondary PSD anchoring point at their PDZ 
binding motif, which would result in their increased stability at the 
PSD. This increased stabilization would not go in detriment of the 
well-described dispersion of α1 and α2 isoforms from the PSD upon 
synaptic activation, as dispersed isoforms rapidly return to the PSD 
(Araki, Zeng, Zhang, & Huganir, 2015; Yang et al., 2013; Yang, Tao-
Cheng, Reese, & Dosemeci, 2011). Furthermore, the low abundance 
of α1 isoforms in the cytosol suggests that at any given time the 
proportion of α1 isoforms outside the PSD is relatively small.
In summary, we have identified clear developmental expression 
pattern differences between SynGAP isoforms, particularly during 
the critical period of Syngap1 haploinsufficiency, which could have 
relevance to brain development and mental illness. Furthermore, 
we provide strong evidence showing that SynGAP, generally re-
garded as a protein exclusive to the PSD, is also found in the cyto-
sol, where it is most abundant during postnatal brain development. 
Different isoforms present clearly distinctive subcellular distribu-
tion, being α1 isoforms highly restricted to the PSD, β ones mainly 
cytosolic and α2 isoforms presenting an intermediate behavior. 
We have observed that the presence of α2 and β isoforms in the 
PSD is developmentally regulated and coincides with the increased 
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expression of α1 isoforms, while a non-synaptic role could be attri-
bute to these less known isoforms. Understanding the functional 
differences between these isoforms will be key to disentangle the 
multiple functions performed by the SynGAP protein.
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